What is MB Research Laboratories?
Established in 1972, MB Research Laboratories operates as a premier Contract Research Organization (CRO) providing critical toxicology testing services to the pharmaceutical, biotechnology, and consumer product sectors. The company distinguishes itself through a deep-rooted expertise in in-vitro and mechanistic toxicity assessments, maintaining a competitive edge by pioneering non-animal predictive technologies. With a robust infrastructure that adheres to stringent GLP standards and complies with international OECD, FDA, and EPA guidelines, the firm serves as a vital partner for entities navigating complex safety and efficacy requirements. Their long-standing history of innovation in alternative testing methods positions them as a leader in the evolving landscape of ethical and efficient drug development.
How much funding has MB Research Laboratories raised?
MB Research Laboratories has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in MB Research Laboratories
PPP
Public-Private Partnership
What's next for MB Research Laboratories?
With the recent capital deployment, MB Research Laboratories is well-positioned to accelerate its R&D initiatives, specifically focusing on the expansion of its proprietary non-animal testing platforms. As the global regulatory environment increasingly shifts toward reducing animal reliance in safety assessments, the company is poised to capture additional market share by scaling its laboratory capacity and enhancing its custom-designed toxicity evaluation services. Future growth will likely center on deepening its footprint in the EU and US markets, leveraging its established reputation for regulatory compliance to meet the rising demand for sophisticated, data-driven toxicology solutions in the biotech and agri-chemical industries.
See full MB Research Laboratories company page
